-
1
-
-
77955283910
-
British thoracic society guideline for non- cf bronchiectasis
-
British Thoracic Society Bronchiectasis non-CF Guideline Group
-
Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non- CF bronchiectasis. Thorax 2010;65:i1-i58.
-
(2010)
Thorax
, vol.65
-
-
Pasteur, M.C.1
Bilton, D.2
Hill, A.T.3
-
2
-
-
0022531170
-
Inflammation: A two-edged sword- The model of bronchiectasis
-
Cole PJ. Inflammation: a two-edged sword- the model of bronchiectasis. Eur J Respir Dis Suppl 1986;147:6-15.
-
(1986)
Eur J Respir Dis Suppl
, vol.147
, pp. 6-15
-
-
Cole, P.J.1
-
3
-
-
84868207364
-
Immunity and bacterial colonisation in bronchiectasis
-
Whitters D, Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax 2012;67:1006-1013.
-
(2012)
Thorax
, vol.67
, pp. 1006-1013
-
-
Whitters, D.1
Stockley, R.2
-
4
-
-
84867114791
-
Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis
-
Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012;186:657-665.
-
(2012)
Am J Respir Crit Care Med
, vol.186
, pp. 657-665
-
-
Chalmers, J.D.1
Smith, M.P.2
McHugh, B.J.3
Doherty, C.4
Govan, J.R.5
Hill, A.T.6
-
5
-
-
0033773862
-
An investigation into causative factors in patients with bronchiectasis
-
Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, Flower CD, Bilton D, Keogan MT. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162:1277-1284.
-
(2000)
Am J Respir Crit Care Med
, vol.162
, pp. 1277-1284
-
-
Pasteur, M.C.1
Helliwell, S.M.2
Houghton, S.J.3
Webb, S.C.4
Foweraker, J.E.5
Coulden, R.A.6
Flower, C.D.7
Bilton, D.8
Keogan, M.T.9
-
6
-
-
0036143373
-
Bacterial colonisation in patients with bronchiectasis: Microbiological pattern and risk factors
-
Angrill J, Agust́i C, de Celis R, Rañó A, Gonzalez J, Solé T, Xaubet A, Rodriguez-Roisin R, Torres A. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57:15-19.
-
(2002)
Thorax
, vol.57
, pp. 15-19
-
-
Angrill, J.1
Agust́i, C.2
De Celis, R.3
Rañó, A.4
Gonzalez, J.5
Solé, T.6
Xaubet, A.7
Rodriguez-Roisin, R.8
Torres, A.9
-
7
-
-
36348949002
-
Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis
-
Mart́inez-GarćiaMA, Soler-Cataluña JJ, Perpiñá-TorderaM, Romá n-Sá nchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132:1565-1572.
-
(2007)
Chest
, vol.132
, pp. 1565-1572
-
-
Mart́inez-Garćia, M.A.1
Soler-Cataluña, J.J.2
Perpiñá-Tordera M Romá, N.3
Sánchez P Soriano, J.4
-
8
-
-
34250636811
-
Microbiologic follow-up study in adult bronchiectasis
-
King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007;101:1633-1638.
-
(2007)
Respir Med
, vol.101
, pp. 1633-1638
-
-
King, P.T.1
Holdsworth, S.R.2
Freezer, N.J.3
Villanueva, E.4
Holmes, P.W.5
-
9
-
-
84879963088
-
Clinical measures of disease in adult non-cf bronchiectasis correlate with airway microbiota composition
-
Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, Serisier DJ. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013;68:731-737.
-
(2013)
Thorax
, vol.68
, pp. 731-737
-
-
Rogers, G.B.1
Van Der Gast, C.J.2
Cuthbertson, L.3
Thomson, S.K.4
Bruce, K.D.5
Martin, M.L.6
Serisier, D.J.7
-
10
-
-
84877918651
-
Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation
-
Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, Ennis M, Boucher RC, Wolfgang MC, Elborn JS. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013; 187:1118-1126.
-
(2013)
Am J Respir Crit Care Med
, vol.187
, pp. 1118-1126
-
-
Tunney, M.M.1
Einarsson, G.G.2
Wei, L.3
Drain, M.4
Klem, E.R.5
Cardwell, C.6
Ennis, M.7
Boucher, R.C.8
Wolfgang, M.C.9
Elborn, J.S.10
-
11
-
-
0030991452
-
Effects of airway infection by pseudomonas aeruginosa: A computed tomographic study
-
Miszkiel KA, Wells AU, Rubens MB, Cole PJ, Hansell DM. Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study. Thorax 1997;52:260-264.
-
(1997)
Thorax
, vol.52
, pp. 260-264
-
-
Miszkiel, K.A.1
Wells, A.U.2
Rubens, M.B.3
Cole, P.J.4
Hansell, D.M.5
-
12
-
-
70349637821
-
Mortality in bronchiectasis: A long-term study assessing the factors influencing survival
-
Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34: 843-849.
-
(2009)
Eur Respir J
, vol.34
, pp. 843-849
-
-
Loebinger, M.R.1
Wells, A.U.2
Hansell, D.M.3
Chinyanganya, N.4
Devaraj, A.5
Meister, M.6
Wilson, R.7
-
13
-
-
0033841109
-
Tobramycin solution for inhalation reduces sputum pseudomonas aeruginosa density in bronchiectasis
-
Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O'Donnell A, Sahn SA, Smith LJ, Stewart JO, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162: 481-485.
-
(2000)
Am J Respir Crit Care Med
, vol.162
, pp. 481-485
-
-
Barker, A.F.1
Couch, L.2
Fiel, S.B.3
Gotfried, M.H.4
Ilowite, J.5
Meyer, K.C.6
O'Donnell, A.7
Sahn, S.A.8
Smith, L.J.9
Stewart, J.O.10
-
14
-
-
19044398177
-
A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis
-
Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005;127:1420-1426.
-
(2005)
Chest
, vol.127
, pp. 1420-1426
-
-
Scheinberg, P.1
Shore, E.2
-
15
-
-
11144228397
-
Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with pseudomonas aeruginosa
-
Drobnic ME, Suñé P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39:39-44.
-
(2005)
Ann Pharmacother
, vol.39
, pp. 39-44
-
-
Drobnic, M.E.1
Suñé, P.2
Montoro, J.B.3
Ferrer, A.4
Orriols, R.5
-
16
-
-
79951824943
-
A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis
-
Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183:491-499.
-
(2011)
Am J Respir Crit Care Med
, vol.183
, pp. 491-499
-
-
Murray, M.P.1
Govan, J.R.2
Doherty, C.J.3
Simpson, A.J.4
Wilkinson, T.S.5
Chalmers, J.D.6
Greening, A.P.7
Haslett, C.8
Hill, A.T.9
-
17
-
-
84877093743
-
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: A phase ii randomised study
-
Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O'Donnell A, Alder J, Reimnitz P, Hampel B. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41:1107-1115.
-
(2013)
Eur Respir J
, vol.41
, pp. 1107-1115
-
-
Wilson, R.1
Welte, T.2
Polverino, E.3
De Soyza, A.4
Greville, H.5
O'Donnell, A.6
Alder, J.7
Reimnitz, P.8
Hampel, B.9
-
18
-
-
84881556337
-
Orbit-2 investigators inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (orbit-2): A randomised, double-blind, placebocontrolled trial
-
Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I; ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebocontrolled trial. Thorax 2013;68:812-817.
-
(2013)
Thorax
, vol.68
, pp. 812-817
-
-
Serisier, D.J.1
Bilton, D.2
De Soyza, A.3
Thompson, P.J.4
Kolbe, J.5
Greville, H.W.6
Cipolla, D.7
Bruinenberg, P.8
Gonda, I.9
-
19
-
-
84898978178
-
Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (azli) for non-cystic fibrosis bronchiectasis (ncfb)
-
September, 2013, Barcelona, Spain. Abstract P4136
-
Barker AF. Two Phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non-cystic fibrosis bronchiectasis (NCFB). Presented at the European Respiratory Society Annual Congress. September, 2013, Barcelona, Spain. Abstract P4136.
-
Presented at the European Respiratory Society Annual Congress
-
-
Barker, A.F.1
-
20
-
-
84866122783
-
British thoracic society national bronchiectasis audit 2010 and 2011
-
British Thoracic Society
-
Hill AT, Welham S, Reid K, Bucknall CE; British Thoracic Society. British Thoracic Society national bronchiectasis audit 2010 and 2011. Thorax 2012;67:928-930.
-
(2012)
Thorax
, vol.67
, pp. 928-930
-
-
Hill, A.T.1
Welham, S.2
Reid, K.3
Bucknall, C.E.4
-
21
-
-
77950606953
-
The adaptive aerosol delivery (aad) technology: Past, present, and future
-
Denyer J, Dyche T. The adaptive aerosol delivery (AAD) technology: past, present, and future. J AerosolMed PulmDrug Deliv 2010;23:S1-S10.
-
(2010)
J AerosolMed PulmDrug Deliv
, vol.23
-
-
Denyer, J.1
Dyche, T.2
-
22
-
-
84887341631
-
Multicenter randomized double blind placebo controlled trial of promixin (colistin) delivered through the i-neb in patients with non-cf bronchiectasis and chronic pseudomonas aeruginosa infection [abstract]
-
Haworth C, Foweraker J, Wilkinson P, Kenyon R, Bilton D. Multicenter randomized double blind placebo controlled trial of Promixin (colistin) delivered through the I-neb in patients with non-CF bronchiectasis and chronic Pseudomonas aeruginosa infection [abstract]. Am J Respir Crit Care Med 2013;187:A3511.
-
(2013)
Am J Respir Crit Care Med
, vol.187
-
-
Haworth, C.1
Foweraker, J.2
Wilkinson, P.3
Kenyon, R.4
Bilton, D.5
-
23
-
-
85027720729
-
Nebulised colistimethate sodium improves quality of life in patients with bronchiectasis colonized with pseudomonas aeruginosa
-
September, 2013, Barcelona, Spain. Abstract 2732
-
Haworth C, Bilton D, Kenyon R. Nebulised colistimethate sodium improves quality of life in patients with bronchiectasis colonized with Pseudomonas aeruginosa. Presented at the European Respiratory Society Annual Congress. September, 2013, Barcelona, Spain. Abstract 2732.
-
Presented at the European Respiratory Society Annual Congress
-
-
Haworth, C.1
Bilton, D.2
Kenyon, R.3
-
24
-
-
84898965355
-
Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
-
September, 2013, Barcelona, Spain. Abstract 4650
-
Haworth C, Bilton D, Kenyon R. Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis. Presented at the European Respiratory Society Annual Congress. September, 2013, Barcelona, Spain. Abstract 4650.
-
Presented at the European Respiratory Society Annual Congress
-
-
Haworth, C.1
Bilton, D.2
Kenyon, R.3
-
25
-
-
0026871146
-
A self-complete measure of health status for chronic airflow limitation. The st. George's respiratory questionnaire
-
Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145: 1321-1327.
-
(1992)
Am Rev Respir Dis
, vol.145
, pp. 1321-1327
-
-
Jones, P.W.1
Quirk, F.H.2
Baveystock, C.M.3
Littlejohns, P.4
-
26
-
-
62949217788
-
Comparison of methods to assess medication adherence and classify nonadherence
-
Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother 2009;43:413-422.
-
(2009)
Ann Pharmacother
, vol.43
, pp. 413-422
-
-
Hansen, R.A.1
Kim, M.M.2
Song, L.3
Tu, W.4
Wu, J.5
Murray, M.D.6
-
27
-
-
84880078608
-
B301 investigators phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cf bronchiectasis
-
Bilton D, Daviskas E, Anderson SD, Kolbe J, King G, Stirling RG, Thompson BR, Milne D, Charlton B. B301 Investigators. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-CF bronchiectasis. Chest 2013;144:215-225.
-
(2013)
Chest
, vol.144
, pp. 215-225
-
-
Bilton, D.1
Daviskas, E.2
Anderson, S.D.3
Kolbe, J.4
King, G.5
Stirling, R.G.6
Thompson, B.R.7
Milne, D.8
Charlton, B.9
-
28
-
-
84865131777
-
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (embrace): A randomised, double-blind, placebo-controlled trial
-
Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380:660-667.
-
(2012)
Lancet
, vol.380
, pp. 660-667
-
-
Wong, C.1
Jayaram, L.2
Karalus, N.3
Eaton, T.4
Tong, C.5
Hockey, H.6
Milne, D.7
Fergusson, W.8
Tuffery, C.9
Sexton, P.10
-
29
-
-
84875524849
-
Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The bat randomized controlled trial
-
Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309:1251-1259.
-
(2013)
JAMA
, vol.309
, pp. 1251-1259
-
-
Altenburg, J.1
De Graaff, C.S.2
Stienstra, Y.3
Sloos, J.H.4
Van Haren, E.H.5
Koppers, R.J.6
Van Der Werf, T.S.7
Boersma, W.G.8
-
30
-
-
0036196105
-
Interpreting thresholds for a clinically significant change in health status in asthma and copd
-
Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002;19: 398-404.
-
(2002)
Eur Respir J
, vol.19
, pp. 398-404
-
-
Jones, P.W.1
-
31
-
-
0030753764
-
Validation of the st. George's respiratory questionnaire in bronchiectasis
-
Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997;156:536-541.
-
(1997)
Am J Respir Crit Care Med
, vol.156
, pp. 536-541
-
-
Wilson, C.B.1
Jones, P.W.2
O'Leary, C.J.3
Cole, P.J.4
Wilson, R.5
-
32
-
-
23744436962
-
Quality-of-life determinants in patients with clinically stable bronchiectasis
-
Mart́inez-Garćia MA, Perpiñá-Tordera M, Romá n-Sá nchez P, Soler- Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005;128:739-745.
-
(2005)
Chest
, vol.128
, pp. 739-745
-
-
Mart́inez-Garćia, M.A.1
Perpiñá Tordera, M.2
Romá, N.3
Sánchez, P.4
Soler-Cataluña, J.J.5
-
33
-
-
84875543900
-
Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The bless randomized controlled trial
-
Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013;309:1260-1267.
-
(2013)
JAMA
, vol.309
, pp. 1260-1267
-
-
Serisier, D.J.1
Martin, M.L.2
McGuckin, M.A.3
Lourie, R.4
Chen, A.C.5
Brain, B.6
Biga, S.7
Schlebusch, S.8
Dash, P.9
Bowler, S.D.10
-
34
-
-
0032968947
-
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
-
Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179:1190-1196.
-
(1999)
J Infect Dis
, vol.179
, pp. 1190-1196
-
-
Burns, J.L.1
Van Dalfsen, J.M.2
Shawar, R.M.3
Otto, K.L.4
Garber, R.L.5
Quan, J.M.6
Montgomery, A.B.7
Albers, G.M.8
Ramsey, B.W.9
Smith, A.L.10
|